HBK Investments’s Coherus Oncology CHRS Stock Holding History

HBK Investments’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-31,100	Closed	-$513K	–	1216
2018 Q3	$513K	Buy	31,100 +17,300	+125%	+$307K	﹤0.01%	929
2018 Q2	$193K	Buy	+13,800	New	+$198K	﹤0.01%	965
2017 Q2	–	Sell	-33,700	Closed	-$713K	–	923
2017 Q1	$713K	Buy	33,700 +23,819	+241%	+$586K	0.01%	465
2016 Q4	$278K	Sell	9,881 -53,619	-84%	-$1.5M	﹤0.01%	642
2016 Q3	$1.7M	Buy	+63,500	New	+$1.73M	0.02%	410

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBK Investments's CHRS Position: Q4 2018 in Review

HBK Investments sold out of Coherus Oncology (CHRS) in Q4 2018, closing a stake of 31,100 shares — an estimated $513K sold.

HBK Investments first reported a position in CHRS in Q3 2016 and held it in 5 quarters. The position peaked at $1.7M in Q3 2016. 111 funds tracked by Wall St. Rank hold CHRS as of Q4 2018.

HBK Investments reported no remaining Coherus Oncology position as of Q4 2018 after selling out during the quarter.
HBK Investments sold 31,100 Coherus Oncology shares in Q4 2018, an estimated $513K.
HBK Investments first reported a position in Coherus Oncology in Q3 2016 and held it in 5 quarters.
HBK Investments's Coherus Oncology position peaked at $1.7M in Q3 2016.
111 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2018.

Based on HBK Investments's 13F filing for Q4 2018, filed 14 Feb 2019.